

Marcello Curvietto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7532221/publications.pdf>

Version: 2024-02-01

12
papers

770
citations

1163117

8
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

1691
citing authors

#	ARTICLE	IF	CITATIONS
1	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28780.	4.6	318
2	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	4.2	230
3	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008842.	4.6	72
4	Serious haematological toxicity during and after ipilimumab treatment: a case series. <i>Journal of Medical Case Reports</i> , 2014, 8, 240.	0.8	50
5	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. <i>Oncolmmunology</i> , 2017, 6, e1283462.	4.6	34
6	Do BRAF inhibitors select for populations with different disease progression kinetics?. <i>Journal of Translational Medicine</i> , 2013, 11, 61.	4.4	25
7	Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8573-8573.	1.6	13
8	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. <i>Oncotarget</i> , 2018, 9, 12408-12417.	1.8	11
9	Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. <i>PLoS ONE</i> , 2019, 14, e0210330.	2.5	6
10	SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9598-TPS9598.	1.6	5
11	Nivolumab for the treatment of small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 5-13.	2.5	4
12	BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9109-TPS9109.	1.6	0